Feasibility of double-blind clinical trials with oral diacetylmorphine: A randomized controlled Phase II study in an inpatient setting

European Addiction Research

Volumn 18, Issue 6, 2012, Pages 279-287

  Farran, Joan Colom ^a   Casas, Miguel ^b,c,g   Pérez De Los Cobos, José ^c,d   Del Río, Miquel ^e   Roncero, Carlos ^b,c,g   Castells, Xavier ^b,c,f   Valero, Sergi ^b,c,g   Eiroa Orosa, Francisco José ^b,c,g   Batlle, Francisca ^c,d   Trujols, Joan ^d,g  

^a AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f UNIVERSITY OF GIRONA   (Spain)

^g CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Double blind randomized clinical trial; Feasibility studies; Immediate release oral diacetylmorphine; Methadone; Opiate dependence; Slow release oral morphine

Indexed keywords

DIAMORPHINE; METHADONE; MORPHINE;

ADULT; ARTICLE; BACKALGIA; CHALAZION; CLINICAL ARTICLE; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; CONVULSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; EPIGASTRIC PAIN; FEASIBILITY STUDY; FEMALE; HEADACHE; HEART BLOCK; HEROIN DEPENDENCE; HUMAN; HYPOTENSION; INSOMNIA; MALE; MULTICENTER STUDY; OTOTUBARITIS; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PILOT STUDY; PNEUMONIA; POSTTRAUMATIC PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TOOTH PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ADDICTION; CONTROLLED CLINICAL TRIAL; DELAYED RELEASE FORMULATION; HOSPITAL PATIENT; METHODOLOGY; OPIATE SUBSTITUTION TREATMENT; ORAL DRUG ADMINISTRATION; PHYSICIAN; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; STATISTICS;

ADMINISTRATION, ORAL; ADULT; BEHAVIOR, ADDICTIVE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEASIBILITY STUDIES; FEMALE; HEROIN; HEROIN DEPENDENCE; HUMANS; INPATIENTS; MALE; METHADONE; MORPHINE; OPIATE SUBSTITUTION TREATMENT; PHYSICIANS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES;

EID: 84864400602     PISSN: 10226877     EISSN: 14219891     Source Type: Journal    
DOI: 10.1159/000336849     Document Type: Article

References (54)

1. European Monitoring Centre for Drugs and Drug Addiction: Annual Report 2008: The State of the Drugs Problem in Europe. Luxembourg, Office for Official Publications of the European Communities, 2011.
2. United Nations: Office of Drug and Crime: World Drug Annual Report 2011. Vienna, United Nations Publications, 2011.
3. Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, McLaren J: Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta-analysis of cohort studies. Addiction 2011; 106: 32-51.
4. Haasen C, van den Brink W: Innovations in agonist maintenance treatment of opioid-dependent patients. Curr Opin Psychiatry 2006; 19: 631-636.
5. Dole VP: What have we learned from three decades of methadone maintenance treatment?. Drug Alcohol Rev 1994; 13: 3-4.
6. Kreek MJ: Methadone-related opioid agonist pharmacotherapy for heroin addiction: History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci 2000; 909: 186-216.
7. Mattick RP, Breen C, Kimber J, Davoli M: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009;CD002209.
8. Gowing LR, Farrell M, Bornemann R: Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med 2006; 21: 193-195.
9. Brugal MT, Domingo-Salvany A, Puig R, Barrio G, García de Olalla P, de la Fuente L: Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 2005; 100: 981-989.
10. Marsch LA: The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: A meta-analysis. Addiction 1998; 93: 515-532.
11. Werb D, Kerr T, Marsh D, Li K, Montaner J, Wood E: Effect of methadone treatment on incarceration rates among injection drug users. Eur Addict Res 2008; 14: 143-149.
12. Torrens M, San L, Martinez A, Castillo C, Domingo-Salvany A, Alonso J: Use of the Nottingham health profile for measuring health status of patients in methadone maintenance treatment. Addiction 1997; 92: 707-716.
13. Maremmani I, Pani PP, Pacini M, Perugi G: Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenancetreated heroin-addicted patients. J Subst Abuse Treat 2007; 33: 91-98.
14. Farré M, Mas A, Torrens M, Moreno V, Camí J: Retention rate and illicit opioid use during methadone maintenance interventions: A meta-analysis. Drug Alcohol Depend 2002; 65: 283-290.
15. Gossop M (ed): Treating Drug Misuse Problems: Evidence of Effectiveness. London, National Treatment Agency for Substance Misuse, 2006.
16. Schwartz RP, Jaffe JH, O'Grady KE, Kinlock TW, Gordon MS, Kelly SM, Wilson ME, Ahmed A: Interim methadone treatment: Impact on arrests. Drug Alcohol Depend 2009; 103: 148-154.
17. Pani PP, Maremmani I, Pacini M, Lamanna F, Maremmani AGI, dell'Osso L: Effect of psychiatric severity on the outcome of methadone maintenance treatment. Eur Addict Res 2011; 17: 80-89.
18. Mino A, Page D, Dumont P, Broers B: Treatment failure and methadone dose in a public methadone maintenance treatment programme in Geneva. Drug Alcohol Depend 1998; 50: 233-239.
19. Morral AR, Belding MA, Iguchi MY: Identifying methadone maintenance clients at risk for poor treatment response: Pretreatment and early progress indicators. Drug Alcohol Depend 1999; 55: 25-33.
20. Jones ES, Moore BA, Sindelar JL, O'Connor PG, Schottenfeld RS, Fiellin DA: Cost analysis of clinic and office-based treatment of opioid dependence: Results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend 2009; 99: 132-140.
21. Mattick RP, Kimber J, Breen C, Davoli M: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008;CD002207.
22. Kraigher D, Jagsch R, Gombas W, Ortner R, Eder H, Primorac A, Fischer G: Use of slowrelease oral morphine for the treatment of opioid dependence. Eur Addict Res 2005; 11: 145-151.
23. Kastelic A, Dubajic G, Strbad E: Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression. Addiction 2008; 103: 1837-1846.
24. Giacomuzzi S, Kemmler G, Ertl M, Riemer Y: Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants. Subst Use Misuse 2006; 41: 223-244.
25. Hartnoll RL, Mitcheson MC, Battersby A, Brown G, Ellis M, Fleming P, Hedley N: Evaluation of heroin maintenance in controlled trial. Arch Gen Psychiatry 1980; 37: 877-884.
26. Drucker E: Injectable heroin substitution treatment for opioid dependency. Lancet 2001; 358: 1385-1385.
27. Lintzeris N: Prescription of heroin for the management of heroin dependence: Current status. CNS Drugs 2009; 23: 463-476.
28. Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A: Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study. Lancet 2001; 358: 1417-1420.
29. Perneger TV, Giner F, del Rio M, Mino A: Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ 1998; 317: 13-18.
30. van den Brink W, Hendriks VM, Blanken P, Koeter MWJ, van Zwieten BJ, van Ree JM: Medical prescription of heroin to treatment resistant heroin addicts: Two randomised controlled trials. BMJ 2003; 327: 310.
31. March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F: Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat 2006; 31: 203-211.
32. Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D: Heroin-assisted treatment for opioid dependence: Randomised controlled trial. Br J Psychiatry 2007; 191: 55-62.
33. Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT: Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med 2009; 361: 777-786.
34. Strang J, Metrebian N, Lintzeris N, Potts L, Carnwath T, Mayet S, Williams H, Zador D, Evers R, Groshkova T, Charles V, Martin A, Forzisi L: Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): A randomised trial. Lancet 2010; 375: 1885-1895.
35. Haasen C, Verthein U, Eiroa-Orosa FJ, Schäfer I, Reimer J: Is heroin-assisted treatment effective for patients with no previous maintenance treatment?. Results from a German randomised controlled trial. Eur Addict Res 2010; 16: 124-130.
36. Mino A: Scientific Analysis of the Literature on the Controlled Provision of Heroin or Morphine. Berne, Federal Office of Public Health, 1990.
37. Frick U, Rehm J, Kovacic S, Ammann J, Uchtenhagen A: A prospective cohort study on orally administered heroin substitution for severely addicted opioid users. Addiction 2006; 101: 1631-1639.
38. Girardin F, Rentsch KM, Schwab MA, Maggiorini M, Pauli-Magnus C, Kullak-Ublick GA, Meier PJ, Fattinger K: Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. Clin Pharmacol Ther 2003; 74: 341-352.
39. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4, text rev. Washington, American Psychiatric Association, 2000.
40. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD: Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987; 13: 293-308.
41. Freyd M: The graphic rating scale. J Educ Psychol 1923; 14: 83-102.
42. National Institute of Mental Health: CGI: Clinical global impressions; in Guy W (ed): Manual for the ECDEU Assessment Battery, ed 2 rev. Bethesda, Chevy Chase, 1970, pp 121-126.
43. Beck A, Ward C, Mendelson M, Mock J, Erbaugh JK: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571.
44. Spielberger CD, Gorsuch RL, Lushene RE: Manual for the State-Trait Anxiety Inventory. Palo Alto, Consulting Psychologists Press, 1970.
45. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M: The fifth edition of the addiction severity index. J Subst Abuse Treat 1992; 9: 199-213.
46. Frick U, Rehm J, Zullino D, Fernando M, Wiesbeck G, Ammann J, Uchtenhagen A: Longterm follow-up of orally administered diacetylmorphine substitution treatment. Eur Addict Res 2010; 16: 131-138.
47. Halbsguth U, Rentsch KM, Eich-Hochli D, Diterich I, Fattinger K: Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: Bioavailability related to dosage and prior opioid exposure. Br J Clin Pharmacol 2008; 66: 781-791.
48. Mitchell TB, White JM, Somogyi AA, Bochner F: Comparative pharmacodynamics and pharmacokinetics of methadone and slowrelease oral morphine for maintenance treatment of opioid dependence. Drug Alcohol Depend 2003; 72: 85-94.
49. Inturrisi C, Max M, Foley K, Schultz M, Shin S, Houde R: The pharmacokinetics of heroin in patients with chronic pain. N Engl J Med 1984; 310: 1213-1217.
50. Perger L, Rentsch KM, Kullak-Ublick GA, Verotta D, Fattinger K: Oral heroin in opioid-dependent patients: Pharmacokinetic comparison of immediate and extended release tablets. Eur J Pharm Sci 2009; 36: 421-432.
51. Dole VP, Nyswander ME, Kreek MJ: Narcotic blockade. Arch Intern Med 1966; 118: 304-309.
52. Cohen J (ed): Statistical Power Analysis for the Behavioral Sciences. Hillsdale, Erlbaum, 1988.
53. Crettol S, Deglon J-J, Besson J, Croquette-Krokkar M, Gothuey I, Hammig R, Monnat M, Huttemann H, Baumann P, Eap CB: Methadone enantiomer plasma levels, cyp2b6, cyp2c19, and cyp2c9 genotypes, and response to treatment. Clin Pharmacol Ther 2005; 78: 593-604.
54. Adinoff B: Divided doses for methadone maintenance. Am J Psychiatry 2008; 165: 303-305.